Regal Assets Analytics

About Bill Langbein

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

Probability Sentiment on FDA decision for Amryt’s (AMYT) rare skin disease drug

By |2022-01-24T12:08:46-05:00January 22nd, 2022|Tags: |

Amryt Pharma plc (NASDAQ:AMYT) Probability Sentiment SUMMARY Amryt Pharma has cobbled together a portfolio of [...]

SanaCurrents Probability Sentiment on PDS Biotechnology’s (PDSB) HBV-specific approach to cervical cancer

By |2022-01-16T12:21:13-05:00January 14th, 2022|Tags: |

 SanaCurrents assigns an advantageous probability PDS Biotechnology and its partner, the MD Anderson Cancer Center, will report positive data later this year from their cervical cancer trial, which combines PDS0101 and chemoradiation therapy.

SanaCurrents on Akebia’s (AKBA) Upcoming PDUFA Decision for CKD Anemia Drug – Speculative Sentiment

By |2022-01-09T11:39:10-05:00January 8th, 2022|Tags: |

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Probability Sentiment SUMMARY Akebia Therapeutics’ vadadustat belongs to a class of [...]

SanaCurrents Closed Coverage of Annexon (ANNX) on Conflicting Phase II Interim Data in Huntington’s Disease

By |2022-01-08T13:02:51-05:00January 7th, 2022|Tags: |

When SanaCurrents issued its report on October 30, 2020, Annexon’s stock closed at $20.81 per share. The stock reached a high of $33.89 per share in March 2021 before leveling to a $20 to $22 per share range between May and mid-October. Annexon began to feel the biotech pull back in the latter months of last year, dropping to slightly more than $10 per share.

Portfolio Update: Closing out ARCT, BTCY, MRNS, KRON, AFIB; new approach to PDUFA catalysts

By |2022-01-08T10:12:03-05:00December 29th, 2021|Tags: , , , , |

As noted in November 2021, Arcturus Therapeutics (NASDAQ:ARCT) was at the forefront of the Covid19 pandemic, teaming up in January [...]

Calliditas’ (CALT) IgAN drug gains FDA approval; SanaCurrents closing out coverage

By |2021-12-20T08:47:54-05:00December 16th, 2021|Tags: |

After the markets closed on December 15, Calliditas Therapeutics said the FDA granted accelerated approval to TARPEYO (budesonide), formerly named [...]

Go to Top